APOE and genetic risk variants influence Alzheimer's disease onset in carriers of an extra copy of APP, with and without Down syndrome.
Genetic variants controlling dementia onset span up to a decade, revealing how biology shapes timing and opening doors for targeted prevention.
APOE ε2 delayed AD onset (HR=0.47) while APOE ε4 accelerated onset (HR=1.5) in APP duplication and Down syndrome carriers; combined APOE plus polygenic AD risk score explained a 10-year span in predicted median age at AD onset. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- Retrospective genetic cohort with Cox survival modeling
- Category
- aging_longevity
- Maturity
- Validated
Why it surfaced
Clarifies the genetic architecture of AD onset variability in APP/Down syndrome carriers—important for both mechanistic understanding and genetic counseling. Published in Alzheimer's & Dementia (top-tier journal); multi-center cohort with DIAN consortium involvement; direct implications for AD prevention trial design in genetically-defined at-risk populations.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.